Skip to main navigation Skip to search Skip to main content

Dissecting rifampicin heteroresistance in Mycobacterium tuberculosis: integrating whole-genome sequencing with phenotypic and clonal validation

  • Katherine Vallejos-Sanchez
  • , Diego A. Taquiri-Díaz
  • , Omar A. Romero-Rodriguez
  • , A. Paula Vargas-Ruiz
  • , Jorge Coronel
  • , Arturo Torres
  • , Jose L. Perez-Martinez
  • , Adiana Ochoa-Ortiz
  • , Robert H. Gilman
  • , Louis Grandjean
  • , Martin Cohen-Gonsaud
  • , Mirko Zimic
  • , Patricia Sheen
  • Universidad Peruana Cayetano Heredia
  • LEGOS, UMR 5566, IRD
  • University College London
  • Johns Hopkins Bloomberg School of Public Health

Research output: Contribution to journalArticlepeer-review

2 Scopus citations

Abstract

Introduction. This study underscores the critical role of identifying heteroresistant infections of Mycobacterium tuberculosis (Mtb) in enhancing the diagnostics of tuberculosis (TB). These conditions complicate diagnostics and treatment, underlining the need for advanced techniques to detect and characterize resistant populations effectively. Hypothesis/Gap statement. Current diagnostics may fail to identify heteroresistance and mixed infections, limiting the understanding of their impact on treatment outcomes. Aim. This pilot study aimed to phenotypically and genotypically characterize rifampicin-heteroresistant clinical isolates and assess their genetic diversity and resistance patterns. Methodology. A retrospective analysis of 2,917 Mtb genomes from Peru (1999–2020) was conducted using MTBseq and TB-Profiler. Techniques included indirect microscopic observation drug susceptibility, MIC determination via tetrazolium microplate assay, agar proportion method and sequencing. From each clinical isolate, three colonies were isolated from both rifampicin-supplemented (1 µg mL−1) and drug-free media for subsequent phenotypic and genotypic characterization, including rpoB sequencing. Results. Of the 2,917 genomes analysed, 14.6% were classified as mixed infections, 3.8% exhibited heteroresistance to at least 1 drug between 21 antibiotics analysed and 0.79% were rifampicin-heteroresistant. Colonies from rifampicin-supplemented media displayed high resistance (MIC >1 µg mL−1) with mutations such as S450L in the RpoB protein. In contrast, those from drug-free media exhibited sensitivity to rifampicin (MIC <1 µg ml−1), harbouring other RpoB mutations including D435Y, L452P and L430P. Notably, some colonies retained WT RpoB sequences, suggesting a diversity of subpopulations within isolates. Conclusion. Whole-genome sequencing and phenotypic analysis confirmed the coexistence of rifampicin-susceptible and rifampicin-resistant Mtb populations within single clinical isolates. Subculturing in drug-free media favoured the selection of sensitive strains, emphasizing the critical need for advanced diagnostic tools to accurately detect and characterize heter-oresistant and mixed infections. These findings pave the way for more targeted treatment strategies to combat antimicrobial resistance in TB.

Original languageEnglish
Article number002048
JournalJournal of Medical Microbiology
Volume74
Issue number7
DOIs
StatePublished - 1 Jul 2025

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • heteroresistance
  • mixed populations
  • rifampicin
  • tuberculosis
  • whole-genome sequencing (WGS)

Fingerprint

Dive into the research topics of 'Dissecting rifampicin heteroresistance in Mycobacterium tuberculosis: integrating whole-genome sequencing with phenotypic and clonal validation'. Together they form a unique fingerprint.

Cite this